- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
FDA Grants Orphan Drug Designation to MB-106 for Waldenstrom Macroglobulinemia Treatment
June 23, 2022
The FDA has granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia. The agent is being investigated in a phase 1/2 clinical trial.
Positive Outcomes of Novel Cellular Therapies Are Seen in Long Relapse, DLBCL
June 17, 2022
Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.
The Road to Improving Diffuse Large B-Cell Lymphoma Treatment
June 15, 2022
In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.
Promising Efficacy Results Demonstrated With Epcoritamab in Refractory LBCL
June 13, 2022
Clinically meaningful efficacy seen with epcoritamab in patients with highly refractory large B-cell lymphoma, according to data from the phase 2 EPCORE NHL-1 clinical trial.
Golidocitnib Shows Promising Anti-Tumor Activity, Safety in PTCL
June 11, 2022
Results from JACKPOT8 presented during the 2022 EHA Congress show that golidocitnib has encouraging anti-tumor efficacy and tolerable safety in patients with relapsed or refractory peripheral T-cell lymphoma.
Initial Data of CB-010 in Relapsed/Refractory B-Cell NHL Reported at EHA 2022
June 10, 2022
Data from ANTLER presented during the 2022 EHA Congress show initial findings of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Lisocabtagene Maraleucel Is a Durable Second-line Therapy for Certain Patients with R/R Large B-Cell Lymphoma
June 05, 2022
At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.
Glofitamab Achieves Durable Response in Heavily Pretreated Patients With LBCL
June 04, 2022
According to Michael Dickinson, MBBS, glofitamab is a highly active drug. The agent showed durable response in patients with heavily pretreated large B-cell lymphoma.
Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
June 04, 2022
Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Sugemalimab is Well-Tolerated in Patients With Natural Killer/T-cell Lymphoma
June 03, 2022
Treatment with sugemalimab shown to be well-tolerated and have a consistent safety profile to other studies, according to results of the GEMSTONE-201 trial.